<DOC>
	<DOCNO>NCT00003199</DOCNO>
	<brief_summary>This phase II trial study well give combination chemotherapy peripheral blood stem cell transplant follow aldesleukin sargramostim work treat patient inflammatory stage IIIB metastatic stage IV breast cancer . Drugs use chemotherapy , busulfan , melphalan , thiotepa , work different way stop growth tumor cell , either kill cell stop dividing . A peripheral stem cell transplant may able replace blood-forming cell destroy chemotherapy . This may allow chemotherapy give tumor cell kill . Aldesleukin may stimulate white blood cell kill breast cancer cell . Giving aldesleukin together sargramostim may kill tumor cell</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Blood Stem Cell Transplant Followed By Aldesleukin Sargramostim Treating Patients With Inflammatory Stage IIIB Metastatic Stage IV Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine event-free survival survival patient treat inflammatory ( Stage IIIb ) responsive stage IV breast cancer BUMELTT PBSC support low dose immunotherapy IL2 GM-CSF . SECONDARY OBJECTIVES : II . To determine toxicity combination low-dose IL-2 GM-CSF patient follow HDC BUMELTT PBSC support . OUTLINE : PREPARATIVE REGIMEN : Patients receive busulfan orally ( PO ) every 6 hour day -8 , -7 , -6 ; melphalan IV 30 minute day -5 -4 ; thiotepa IV 2 hour day -3 -2 . TRANSPLANTATION : Patients undergo autologous peripheral blood stem cell infusion day 0 . POST-TRANSPLANT THERAPY : All patient receive tamoxifen citrate* PO daily begin prior aldesleukin ( IL-2 ) sargramostim ( GM-CSF ) therapy continue 5 year relapse ( estrogen receptor [ ER ] - progesterone receptor [ PR ] -positive patient ) OR completion IL-2/GM-CSF therapy ( ER-negative PR-negative patient ) . Eligible patient receive IL-2 subcutaneously ( SC ) daily GM-CSF SC 3 time weekly 12 week begin 30-100 day transplantation . Patients may receive radiotherapy completion IL-2/GM-CSF treatment prior radiotherapy give transplantation . *Stage IV patient receive IL-2/GM-CSF therapy receive tamoxifen citrate part adjuvant therapy subsequently fail , receive oral anastrozole daily 5 year progression instead tamoxifen . [ *For postmenopausal patient , choice duration hormonal therapy give addition alternative tamoxifen therapy physician 's discretion ] Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients inflammatory ( stage IIIb ) responsive stage IV breast cancer metastasis soft tissue and/or bone ; responsive stage IV disease define patient achieve PR ( &gt; = 50 % reduction measurable tumor burden ) CR follow initial chemotherapy metastatic disease patient locally recurrent disease ( chest wall/axillary node ) render diseasefree follow surgery radiation therapy without receive chemotherapy ; bone disease categorize responsive demonstrated sclerosis prior lesion new lesion Patients receive 47 cycle Adriamycin and/or taxanebased regimen stage IIIb stage IV disease ; locally recurrent ( chest wall/axillary node ) patient render NED RT surgery need receive chemotherapy stage IV disease prior Cytoxan/Taxol Patient receive Cytoxan 4 gm/m^2 x 1 Taxol 250 mg/m^2 x 1 per FHCRC protocol 506.03 ; Cytoxan/Taxol must give chemotherapy complete transplant Stem cell collect mobilization Cytoxan/Taxol mobilization FHCRC approve cytokine protocol ; syngeneic collection , PBSC 's collect use GCSF accord FHCRC protocol 753 ; patient adequate number peripheral blood stem cell store ( &gt; = 2.5 x 10^6 CD34+ cells/kg ) The patient must capacity give informed consent ; patient must sign approve consent form conform federal institutional guideline Hepatic function : Bilirubin = &lt; 2 mg % ; SGOT SGPT = &lt; 2.5 x institutional normal Renal function : Creatinine = &lt; 2.0 mg/dl creatinine clearance &gt; = 50 mg/min PreStudy test perform outline Study Calendar Patients begin IL2/GMCSF therapy meet follow criterion posttransplant : Can start therapy 30 100 day transplant Karnofsky performance status &gt; 60 ANC &gt; 1,000 cells/mm^3 platelet &gt; 30,000/cells/mm^3 ( transfusion independent ) least 5 day start therapy Total bilirubin = &lt; 2.5 x upper limit normal SGOT = &lt; 2.5 x upper limit normal Creatinine = &lt; 2.0 mg/dl Patients Karnofsky Performance Score less 70 Patients leave ventricular ejection fraction le 50 % ( LVEF must perform patient symptoms CHF , abnormal cardiac exam history Adriamycin therapy total dose &gt; 400 mg/m^2 ) Patient pregnant Patient seropositive human immunodeficiency virus Patients history seizures Patients hypersensitivity E.coli preparation Patients active autoimmune disease Patients clinically significant pulmonary disease , i.e. , diffusion capacity correct &lt; 60 % predict ; patient pulmonary problem evaluate appropriate pulmonary study and/or consult Patients history CNS lesion ( brain carcinoid meningitis ) Patients significant active infection preclude transplant Patients one prior chemotherapy regimen stage IV disease prior transplant stage disease Patients CD34+ selection PBSC product Patients receive IL2/GMCSF therapy : Are &gt; 100 day transplant Have document disease progression transplant Have active infection Manifested cardiac complication initial transplant period , include arrhythmia ( require therapy ) , congestive heart failure , angina , myocardial infarct , decrease LVEF &lt; 45 % Currently pericardial effusion , pleural effusion ascites Manifested pulmonary toxicity initial transplant period diffusion capacity correct = &lt; 60 % Are steroids Currently Grade 3 toxicity BuMelTT If patient wish receive therapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>